S1900A did not demonstrate the expected level of efficacy for rucaparib in patients with advanced NSCLC exhibiting high genomic LOH and/or BRCA1/2 mutations (Riess et al., 2021). Here, BRCA1 is linked to non-small cell lung carcinoma.